Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy

Shingo Miyamoto, hiroshi yagi, Fusanori Yotsumoto, Tatsuhiko Kawarabayashi, Eisuke Mekada

Research output: Contribution to journalReview article

102 Citations (Scopus)

Abstract

HB-EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB-EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB-EGF. Recent studies have indicated that HB-EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer-derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. CRM197, a specific inhibitor of HB-EGF, and an antibody against HB-EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB-EGF is a promising target for cancer therapy, and that the development of targeting tools against HB-EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors.

Original languageEnglish
Pages (from-to)341-347
Number of pages7
JournalCancer Science
Volume97
Issue number5
DOIs
Publication statusPublished - May 1 2006

Fingerprint

Epidermal Growth Factor
Heparin
Intercellular Signaling Peptides and Proteins
Neoplasms
Therapeutics
Heparin-binding EGF-like Growth Factor
Biological Phenomena
Cell Line
Eyelids
Nude Mice
Wound Healing
Atherosclerosis
Maintenance
Neoplasm Metastasis
Ligands
Phenotype
Gene Expression
Drug Therapy
Skin
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. / Miyamoto, Shingo; yagi, hiroshi; Yotsumoto, Fusanori; Kawarabayashi, Tatsuhiko; Mekada, Eisuke.

In: Cancer Science, Vol. 97, No. 5, 01.05.2006, p. 341-347.

Research output: Contribution to journalReview article

Miyamoto, Shingo ; yagi, hiroshi ; Yotsumoto, Fusanori ; Kawarabayashi, Tatsuhiko ; Mekada, Eisuke. / Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. In: Cancer Science. 2006 ; Vol. 97, No. 5. pp. 341-347.
@article{cc4e2df2ed3547f0810d200ccc1fd3ad,
title = "Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy",
abstract = "HB-EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB-EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB-EGF. Recent studies have indicated that HB-EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer-derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. CRM197, a specific inhibitor of HB-EGF, and an antibody against HB-EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB-EGF is a promising target for cancer therapy, and that the development of targeting tools against HB-EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors.",
author = "Shingo Miyamoto and hiroshi yagi and Fusanori Yotsumoto and Tatsuhiko Kawarabayashi and Eisuke Mekada",
year = "2006",
month = "5",
day = "1",
doi = "10.1111/j.1349-7006.2006.00188.x",
language = "English",
volume = "97",
pages = "341--347",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy

AU - Miyamoto, Shingo

AU - yagi, hiroshi

AU - Yotsumoto, Fusanori

AU - Kawarabayashi, Tatsuhiko

AU - Mekada, Eisuke

PY - 2006/5/1

Y1 - 2006/5/1

N2 - HB-EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB-EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB-EGF. Recent studies have indicated that HB-EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer-derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. CRM197, a specific inhibitor of HB-EGF, and an antibody against HB-EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB-EGF is a promising target for cancer therapy, and that the development of targeting tools against HB-EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors.

AB - HB-EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB-EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB-EGF. Recent studies have indicated that HB-EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer-derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. CRM197, a specific inhibitor of HB-EGF, and an antibody against HB-EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB-EGF is a promising target for cancer therapy, and that the development of targeting tools against HB-EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors.

UR - http://www.scopus.com/inward/record.url?scp=33645540607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645540607&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2006.00188.x

DO - 10.1111/j.1349-7006.2006.00188.x

M3 - Review article

C2 - 16630129

AN - SCOPUS:33645540607

VL - 97

SP - 341

EP - 347

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -